COVID Clinical Trial
Official title:
Retrospective Observational Study to Compare the Short, Mid- and Long-term Prognosis and Outcomes of SRAS-CoV-2 Infected Hospitalized Patients With Cardiovascular Disease (CVD) to SARS-CoV-2 Infected Hospitalized Patients Without CVD: The Geneva Covid-19 CVD Study
Verified date | October 2021 |
Source | University Hospital, Geneva |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
In this study, the investigators propose to analyse the clinical data of all patients admitted in Geneva University Hospitals (HUG) or in a care center in Geneva who are diagnosed with COVID-19. CVD being one of the most important risk factors for developing a severe form of the disease, the investigators will explore the prognosis and clinical outcomes of those patients according to their CVD history as well as newly onset CVD during hospitalization. Moreover, as further evidence is needed on the use of renin-angiotensin-aldosterone system (RAAS) inhibitors for SARS-CoV-2 infected patients, the investigators will study prognosis and outcomes according to the patients' medications. Finally, the investigators propose to evaluate hospital length of stay and cost. The aim, therefore, is to collect information and scientific evidence from patients hospitalized and diagnosed positive for COVID-19, in order to evaluate if previous (or newly onset) CVD may influence outcomes and costs.
Status | Completed |
Enrollment | 1927 |
Est. completion date | July 31, 2021 |
Est. primary completion date | June 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subject is =18 years of age. - Patient diagnosed SARS-CoV-2 positive at time of hospitalization. - In case of the subject accepting the follow-up at 30 days and 1 year, Signed Patient Informed Consent (PIC) form Exclusion Criteria: - Patients unwilling to provide informed consent for the follow-up. |
Country | Name | City | State |
---|---|---|---|
Switzerland | Geneva University Hospital (HUG) | Geneva |
Lead Sponsor | Collaborator |
---|---|
François MACH |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | mobidity discharge | To compare morbidity during hospital stay in COVID-19+ patients with or without preexisting CVD. | 0 days after hospitalization | |
Primary | mobidity at 30 days | To compare morbidity 30 days after hospitalization in COVID-19+ patients with or without preexisting CVD. | 30 days after hospitalization | |
Primary | mobidity 1 year after hospitalization | To compare morbidity 1 year after hospitalization stay in COVID-19+ patients with or without preexisting CVD. | 1 year after hospitalization | |
Primary | mortality discharge | To compare mortality during hospital stay in COVID-19+ patients with or without preexisting CVD. | 0 days after hospitalization | |
Primary | mortality 30 days after hospitalization | To comparemortality30 days after hospital stay in COVID-19+ patients with or without preexisting CVD. | 30 days after hospitalization | |
Primary | mortality 1 year after hospitalization | To compare mortality 1 year after hospital stay in COVID-19+ patients with or without preexisting CVD. | 1 year after hospitalization | |
Secondary | Clinical outcomes according to medication at admission | Clinical outcomes according to medication at admission evaluated at hospital discharge | 0 days after hospitalization | |
Secondary | Clinical outcomes according to medication at admission | Clinical outcomes according to medication at admission evaluated 30 days after hospitalization | 30 days after hospitalization | |
Secondary | Clinical outcomes according to medication at admission | 1 year after hospitalization | 1 year after hospitalization | |
Secondary | Clinical outcomes related to preexisting cardiovascular risk factors at admission | Clinical outcomes related to preexisting cardiovascular risk factors at admission evaluated after hospital discharge | 0 days after hospitalization | |
Secondary | Clinical outcomes related to preexisting cardiovascular risk factors at admission | Clinical outcomes related to preexisting cardiovascular risk factors at admission evaluated 30 days after hospital discharge | 30 days after hospitalization | |
Secondary | Clinical outcomes related to preexisting cardiovascular risk factors at admission | Clinical outcomes related to preexisting cardiovascular risk factors at admission evaluated 1 year after hospitalization | 1 year after hospitalization | |
Secondary | New onset of CVD induced by COVID-19 disease | New onset of CVD induced by COVID-19 disease at discharge | 0 days after hospitalization | |
Secondary | New onset of CVD induced by COVID-19 disease | New onset of CVD induced by COVID-19 disease evaluated 30 days after hospitalization | 30 days after hospitalization | |
Secondary | New onset of CVD induced by COVID-19 disease | New onset of CVD induced by COVID-19 disease at discharge evaluated 1 year after hospitalization | 1 year after hospitalization | |
Secondary | Cost of hospital stay | Cost of hospital stay | 0 days after hospitalization | |
Secondary | Clinical follow up at 30 days (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis). | Clinical follow up at 30 days (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis). | 30 days after hospitalization | |
Secondary | Clinical follow up at 1 year (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis). | Clinical follow up at 1 year (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis). | 1 year after hospitalization |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
Recruiting |
NCT04410510 -
P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04420676 -
Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection
|
N/A | |
Completed |
NCT04419025 -
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
|
Phase 2 | |
Completed |
NCT04395911 -
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
|
N/A | |
Completed |
NCT04425317 -
Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients
|
N/A | |
Withdrawn |
NCT04456426 -
Characteristics of Patients With COVID-19 in Meta State, Colombia
|
||
Completed |
NCT04526769 -
Detecting SARS-CoV-2 in Tears
|
||
Suspended |
NCT04385771 -
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
|
N/A | |
Completed |
NCT04425720 -
Use of Remote Monitoring for COVID-19 Patient
|
N/A | |
Completed |
NCT04419610 -
RAS and Coagulopathy in COVID19
|
Early Phase 1 | |
Completed |
NCT04546581 -
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
|
Phase 3 | |
Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
Completed |
NCT04435327 -
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
|
||
Not yet recruiting |
NCT04524156 -
COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2
|
N/A | |
Completed |
NCT04441710 -
Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
|
||
Completed |
NCT04357834 -
WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
|
||
Not yet recruiting |
NCT04392427 -
New Antiviral Drugs for Treatment of COVID-19
|
Phase 3 | |
Terminated |
NCT04614025 -
Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19
|
Phase 2 | |
Completed |
NCT04402957 -
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
|
Phase 2 |